Literature DB >> 27628949

Grading lung neuroendocrine tumors: Controversies in search of a solution.

Giuseppe Pelosi1, Linda Pattini2, Giovanni Morana3, Alessandra Fabbri4, Alex Faccinetto5, Nicola Fazio6, Barbara Valeri4, Angelica Sonzogni4.   

Abstract

BACKGROUND: Pathological grading of tumors is a way to measure biological aggressiveness. In lung neuroendocrine tumors (NET), grading is tautologically included into the current 2015 WHO histologic classification. Little is known, however, about alternative grading systems in lung NET.
METHODS: Through an extensive search of the English literature on lung NET (updated to April 2016), the following key questions were addressed: a) current concepts of grading; b) clinicians' requests for grading; c) functional parameters for grading; d) Ki-67 labeling index (LI) for grading; e) towards an effective pathology grading system.
RESULTS: There is some room for inconsistency in the histologic classification of lung NET, likely due to the varying attribution of defining criteria. Innovative diffusion-weighted imaging upon magnetic resonance or molecular analysis could help separate indolent from aggressive lung NET, thus integrating a grading approach other than histology. Troubles in the clinical handling of metastatic or individual tumors when relying on morphology alone support the development of a lung-specific grading system for the more accurate prediction of prognosis and planning therapy in individual patients. To integrate the 2015 WHO classification using innovative grading based on Ki-67 LI, mitotic count and necrosis, a new proposal is emerging where three categories of lung NET are identified, namely Lu-NET G1, Lu-NET G2 and Lu-NET G3, which would allow tumors with similar behavior and therapy to be better handled according to their own biological potential.
CONCLUSION: This new formulation of lung NET grading could have clinical relevance for the individual handling of patients.

Entities:  

Mesh:

Year:  2016        PMID: 27628949     DOI: 10.14670/HH-11-822

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  14 in total

Review 1.  The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

Authors:  Nicola Fazio; Antonio Ungaro; Francesca Spada; Chiara Alessandra Cella; Eleonora Pisa; Massimo Barberis; Chiara Grana; Dario Zerini; Emilio Bertani; Dario Ribero; Luigi Funicelli; Guido Bonomo; Davide Ravizza; Juliana Guarize; Filippo De Marinis; Francesco Petrella; Ester Del Signore; Giuseppe Pelosi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  Lung neuroendocrine tumors: pathological characteristics.

Authors:  Luisella Righi; Gaia Gatti; Marco Volante; Mauro Papotti
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  [Report of the Working Group on Thoracic Pathology of the German Society of Pathology 2017].

Authors:  A Fisseler-Eckhoff; A Warth
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

4.  Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities.

Authors:  Lynnette Fernandez-Cuesta; Matthieu Foll
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Mauro Papotti; Luisella Righi; Gaia Gatti; Patrick Maisonneuve; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-01-04       Impact factor: 4.064

Review 6.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

7.  Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Authors:  Sanaz Taromi; Florentine Lewens; Ruza Arsenic; Dagmar Sedding; Jörg Sänger; Almut Kunze; Markus Möbs; Joana Benecke; Helma Freitag; Friederike Christen; Daniel Kaemmerer; Amelie Lupp; Mareike Heilmann; Hedwig Lammert; Claus-Peter Schneider; Karen Richter; Michael Hummel; Britta Siegmund; Meike Burger; Franziska Briest; Patricia Grabowski
Journal:  Oncotarget       Date:  2017-09-23

Review 8.  Systemic treatment for lung carcinoids: from bench to bedside.

Authors:  Mariangela Torniai; Laura Scortichini; Francesca Tronconi; Corrado Rubini; Francesca Morgese; Silvia Rinaldi; Paola Mazzanti; Rossana Berardi
Journal:  Clin Transl Med       Date:  2019-07-04

9.  Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept.

Authors:  Giuseppe Pelosi; Federica Massa; Gaia Gatti; Luisella Righi; Marco Volante; Nadia Birocco; Patrick Maisonneuve; Angelica Sonzogni; Sergio Harari; Adriana Albini; Mauro Papotti
Journal:  Clin Pathol       Date:  2019-02-19

10.  Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.

Authors:  Alberto Bongiovanni; Federica Recine; Flavia Foca; Valentina Fausti; Nada Riva; Greta Fabbri; Stefano Severi; Chiara Liverani; Alessandro De Vita; Chiara Spadazzi; Giacomo Miserocchi; Laura Mercatali; Dino Amadori; Toni Ibrahim
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.